Matthew D. Cascino

Internal Medicine

400 Parnassus Ave
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

Journal: JAMA dermatology

Published: August 26, 2026

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Journal: The New England journal of medicine

Published: March 30, 2026

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Journal: The New England journal of medicine

Published: March 30, 2026

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.

Journal: Clinical immunology (Orlando, Fla.)

Published: November 02, 2022

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

Journal: Annals of the rheumatic diseases

Published: June 03, 2021

Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.

Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.

Journal: Lupus

Published: March 29, 2020

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis.

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis.

Journal: JCI insight

Published: February 20, 2020

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: March 02, 2019

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.

Journal: Lupus science & medicine

Published: October 29, 2018

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Journal: Arthritis care & research

Published: October 09, 2018

MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer.

MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: August 23, 2018

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: January 22, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026